Lakefront Biotherapeutics (LKFT) Research & Development (2016 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Research & Development for 11 consecutive years, with -$35.2 million the latest figure, recorded in Q1 2026.

• Quarterly Research & Development rose 83.06% year-over-year to -$35.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $695.5 million (up 172.47% YoY) and the FY2025 annual result came in at $522.8 million, up 36.95% from the prior year.
• Research & Development slipped to -$35.2 million in Q1 2026 per LKFT's latest filing, from $923.3 million in the prior quarter.
• Over the last five years, Research & Development for LKFT reached as high as $923.3 million in Q4 2025 and fell as low as -$386.2 million in Q3 2025.
• A 5-year average of $128.3 million and a median of -$33.0 million in 2022 frame the typical range for Research & Development.
• The largest YoY upside for Research & Development was 182.15% in 2025 against a maximum downside of 155.19% in 2025.
• Year by year, Research & Development stood at $426.9 million in 2022, then increased by 8.9% to $464.9 million in 2023, then jumped by 40.45% to $652.9 million in 2024, then jumped by 41.41% to $923.3 million in 2025, then plunged by 103.82% to -$35.2 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered -$35.2 million, $923.3 million, and -$386.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.